Fallopian Tube Clear Cell Adenocarcinoma Fallopian Tube Endometrioid Adenocarcinoma Fallopian Tube Mucinous Adenocarcinoma Fallopian Tube Serous Adenocarcinoma Fallopian Tube Transitional Cell Carcinoma Malignant Ovarian Brenner Tumor Ovarian Clear Cell Adenocarcinoma Ovarian Endometrioid Adenocarcinoma Ovarian Mucinous Adenocarcinoma Ovarian Seromucinous Carcinoma Ovarian Serous Adenocarcinoma Ovarian Transitional Cell Carcinoma Primary Peritoneal Serous Adenocarcinoma Stage IIA Fallopian Tube Cancer Stage IIA Ovarian Cancer Stage IIB Fallopian Tube Cancer Stage IIB Ovarian Cancer Stage IIC Fallopian Tube Cancer Stage IIC Ovarian Cancer Stage IIIA Fallopian Tube Cancer Stage IIIA Ovarian Cancer Stage IIIA Primary Peritoneal Cancer Stage IIIB Fallopian Tube Cancer Stage IIIB Ovarian Cancer Stage IIIB Primary Peritoneal Cancer Stage IIIC Fallopian Tube Cancer Stage IIIC Ovarian Cancer Stage IIIC Primary Peritoneal Cancer Stage IV Fallopian Tube Cancer Stage IV Ovarian Cancer Stage IV Primary ...
How can I reduce the risk of fallopian tube cancer? - Female Cancers: the facts - How can I reduce the risk of fallopian tube cancer? Because so little is known about the specific causes of fallopian tube cancer, there is little you can do to clearly lower your chances of developing it...
Fallopian Tube Carcinoma, Hirsutism, Pelvic Pain Symptom Checker: Possible causes include Ovarian Cyst, Epithelial Ovarian Cancer, Ovarian Neoplasm. Check the full list of possible causes and conditions now! Talk to our Chatbot to narrow down your search.
TY - JOUR. T1 - A clinicopthological study of fallopian tube carcinoma. AU - Liu, Wei-Min. AU - Chao, K. C.. AU - Yuan, CC. AU - Chen, CJ. AU - Ng, HT. PY - 1991. Y1 - 1991. M3 - Article. SP - 54. EP - 59. JO - Taiwanese Journal of Obstetrics and Gynecology. JF - Taiwanese Journal of Obstetrics and Gynecology. SN - 1028-4559. ER - ...
Concerned about Fallopian Tube Cancer? Learn about the Facts & Figures, Symptoms of Fallopian Tube Cancer, Diagnosis and the Treatment options.
Complementary and alternative medicine, often abbreviated CAM, may be used in the treatment of illnesses such as fallopian tube cancer. These therapie
Global Markets Directs, \Fallopian Tube Cancer - Pipeline Review, H1 2013\, provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Fallopian Tube Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Fallo
PRIMARY OBJECTIVE:. I. Compare the efficacy of nurse-delivered WRITE Symptoms? and self-directed WRITE Symptoms? vs usual care interventions in improving target symptom representations (i.e., decreases in symptom severity, symptom-related distress, and symptom consequences as measured by the Symptom Representation Questionnaire [SRQ]) in patients with recurrent or persistent ovarian, fallopian tube, or primary peritoneal cancer.. SECONDARY OBJECTIVES:. I. Compare the efficacy of nurse-delivered WRITE Symptoms? vs self-directed WRITE Symptoms? vs usual care interventions in improving target symptom representations in these patients at 4 weeks.. II. Compare the efficacy of nurse-delivered WRITE Symptoms? vs self-directed WRITE Symptoms? vs usual care interventions in improving target symptom controllability in these patients at 4, 8, and 12 weeks.. III. Compare the efficacy of nurse-delivered WRITE Symptoms? vs self-directed WRITE Symptoms? vs usual care interventions in improving indicators of ...
Wendywoo - Spouse/Partner: Ovarian and Fallopian Tube Cancer > Epithelial Ovarian Carcinoma > Serous Type Patient Info: Newly diagnosed (has not begun treatment), Diagnosed: over 7 years ago, Female, Age: 56, Stage IIIC
Damayanti, Z., Ilancheran, A., Ali, A.B., Sng, J.H., Iau, P.T.C. (2006). The founder mutation BRCA1c.2845insA identified in a fallopian tube cancer patient: A case report. International Journal of Gynecological Cancer 16 (SUPPL. 1) : 362-365. [email protected] Repository. https://doi.org/10.1111/j.1525-1438.2006.00221. ...
Fallopian tube carcinomas were once believed to be rare. Some investigators have demonstrated precursor cancerous lesions in the fallopian tube (tubal in-situ carcinoma [TIC]) and have speculated that many advanced serous
Missense mutation of TP53 is the dominant driver in ovarian/fallopian tube cancer [1-4]. Indeed TP53 is mutated in nearly all high grade serous carcinomas (HGSC), the histotype responsible for most deaths from ovarian cancer [5, 6], and is also mutated in its precursor, serous tubal intraepithelial carcinoma (STIC) [7-9], suggesting this is a key and early event in carcinogenesis [10]. In addition to inactivating wild type TP53 function, these mutations frequently confer gain-of -function properties including redirection of Nrf2 to upregulate the proteasome [11]. The aberrant metabolism of ovarian cancer cells produces an excess of misfolded proteins that are polyubiquitinated for targeted degradation via the proteasome, and this is associated with proteasome upregulation [12]. Consequently, ovarian cancer cells are both highly dependent on proteasome function and especially sensitive to treatment with a proteasome inhibitor [12-14]. The FDA-approved drug bortezomib, approved for the treatment ...
High-grade serous ovarian cancer, also known as high-grade serous carcinoma (HGSC), is the most common and deadliest type of ovarian cancer. HGSC appears to arise from the ovary, fallopian tube, or peritoneum. As most HGSC cases present with widespread peritoneal metastases, it is often not clear where HGSC truly originates. Traditionally, the ovarian surface epithelium (OSE) was long believed to be the origin of HGSC. Since the late 1990s, the fallopian tube epithelium has emerged as a potential primary origin of HGSC. Particularly, serous tubal intraepithelial carcinoma (STIC), a noninvasive tumor lesion formed preferentially in the distal fallopian tube epithelium, was proposed as a precursor for HGSC. It was hypothesized that STIC lesions would progress, over time, to malignant and metastatic HGSC, arising from the fallopian tube or after implanting on the ovary or peritoneum. Many clinical studies and several mouse models support the fallopian tube STIC origin of HGSC. Current evidence indicates
Anderson Cancer Center between January 1992 and December 2004 and who did not meet any of the following exclusion criteria: stage III or IV ovarian cancer, appendectomy as part of a second-look procedure or secondary tumor-reductive surgery, primary appendiceal cancer, primary gastrointestinal malignancy with metastasis to the appendix, incomplete clinicopathologic data, appendicitis as a preoperative diagnosis, primary fallopian tube cancer, primary peritoneal cancer, or documented dual primary tumors ...
TY - JOUR. T1 - Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. AU - Walsh, Tom. AU - Casadei, Silvia. AU - Lee, Ming K.. AU - Pennil, Christopher C.. AU - Nord, Alexander. AU - Thornton, Anne M.. AU - Roeb, Wendy. AU - Agnew, Kathy J.. AU - Stray, Sunday M.. AU - Wickramanayake, Anneka. AU - Norquist, Barbara. AU - Pennington, Kathryn P.. AU - Garcia, Rochelle L.. AU - King, Mary Claire. AU - Swisher, Elizabeth M.. PY - 2011/11/1. Y1 - 2011/11/1. N2 - Inherited loss-of-function mutations in BRCA1 and BRCA2 and other tumor suppressor genes predispose to ovarian carcinomas, but the overall burden of disease due to inherited mutations is not known. Using targeted capture and massively parallel genomic sequencing, we screened for germ-line mutations in 21 tumor suppressor genes in genomic DNA from women with primary ovarian, peritoneal, or fallopian tube carcinoma. Subjects were consecutively enrolled at diagnosis ...
Clinical trial for Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer , A Randomized, Open Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® with DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: This phase I trial to studying the side effects of vaccine
The content on this site is for informational purposes only. It is not a substitute for professional medical advice. Do not use this information to diagnose or treat a health problem or disease without consulting with a qualified healthcare provider. Please consult your healthcare provider with any questions or concerns you may have regarding your condition. Use of this online service is subject to the disclaimer and the terms and conditions.. Copyright 2000-2019 © Cancer Survivors Network. ...
Epithelial ovarian, fallopian tube, and primary peritoneal cancers remain the most lethal of all the gynecologic malignancies. In 2010, approximately 21,880 women will be diagnosed with ovarian cancer in the United States; of these, 13,850 will be expected to die from this disease.1 Cancers arising from the fallopian tube and peritoneum are significantly less common that those arising from the ovarian epithelium, but share several similarities in their epidemiology, diagnosis, treatment, and associated outcomes. Because the vast majority of fallopian tube and primary peritoneal cancers exhibit a high-grade papillary serous histology, comparisons to similar disease in primary ovarian cancers suggest common molecular pathways that may promote carcinogenesis within the serous classification of these tumors. Several recent hypotheses also propose a fallopian tube origin for metastatic disease that would traditionally be considered as primary ovarian or peritoneal. Given the recent advances ...
Clinical trial for Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Carcinoma , DEC-205/NY-ESO-1 Fusion Protein CDX-1401 Poly ICLC and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian Fallopian Tube or Primary Peritoneal Cancer in Remission
TY - JOUR. T1 - Expression of TGFβ1 and its receptors is associated with biological features of ovarian cancer and sensitivity to paclitaxel/carboplatin. AU - Komiyama, Shinichi. AU - Kurahashi, Takashi. AU - Ishikawa, Mitsuya. AU - Tanaka, Kyoko. AU - Komiyama, Mizuka. AU - Mikami, Mikio. AU - Udagawa, Yasuhiro. PY - 2011/4. Y1 - 2011/4. N2 - It has been suggested that expression of TGFβ1 and its receptors [TGFβ receptor type I (TβRI) and TGFβ receptor type II (TβRII)] may play a key role in the proliferation and progression of epithelial ovarian cancer. We investigated the biological significance of TGFβ1 and its receptors, as well as their association with the tumor response to paclitaxel (PTX) and carboplatin (CBDCA). We studied 24 patients with ovarian cancer, primary peritoneal cancer, or fallopian tube cancer who had undergone surgery and chemotherapy with PTX and CBDCA. Tissues from the primary tumor were examined and the expression of TGFβ1, TβRI, and TβRII mRNA was assessed ...
Tang S, Onuma, K, Deb P, Wang E, Mahe E, Sur M and Daya D. Frequency of Serous Tubal Intraepithelial Carcinoma in Various Gynecological Malignancies-A Study of 300 Consecutive Cases. Int J Gynecol Path, 2012; 31:103-110.. Quinlan -Davidson S, Hodgson N, Elavathil L, Tang S. Borderline Phyllodes Tumor with an Incidental Invasive Ductal Carcinoma and Lobular Carcinoma In-Situ Component: A Case Report". J Breast Cancer. 2011; 14(3):237-240. He SH, Chen X, Song CH, Liu ZQ, Zhou LF, Ma WE, Zhao LD, Li TL, Tang SG, Xing Z, Yang PC. Interferon- λ-mediates oral tolerance and inhibits antigen-specific, T-helper 2 cell-mediated inflammation in mouse intestine. Gastroenterology. 2011; 141:249-258. 2011. Feng BS, Chen X, Li P, Zheng PY, Chong J, Cho DB, He SH, Tang SG and Yang PC. Expression of integrin alphavbeta6 in the intestinal epithelial cells of patients with inflammatory bowel disease. North Am J Med Sci. 2009; 1: 200-204. 2009. Zheng PY, Feng BS, Oluwole C, Solderholm J, Chen X, Li P, Tang SG and ...
Chapter 9 discusses MR techniques specific to gynecologic imaging, including tissue characterization, anatomy, congenital anomalies, uterine myometrial pathology, and endometrial-origin masses. High-grade malignancies with specific imaging features are also covered, including cervical cancer, adnexal masses, non-neoplastic adnexal masses with classic features ovarian neoplasms, fallopian tube carcinoma, as well as vaginal cancer. ...
Inclusion Criteria: - Female patients with newly diagnosed, histologically confirmed, high risk advanced (FIGO stage III - IV) BRCA mutated high grade serous or high grade endometrioid ovarian cancer, primary peritoneal cancer and / or fallopian - tube cancer who have completed first line platinum based chemotherapy (intravenous or intraperitoneal). - Stage III patients must have had one attempt at optimal debulking surgery (upfront or interval debulking). Stage IV patients must have had either a biopsy and/or upfront or interval debulking surgery. - Documented mutation in BRCA1 or BRCA2 that is predicted to be deleterious or suspected deleterious (known or predicted to be detrimental/lead to loss of function). - Patients who have completed first line platinum (e.g. carboplatin or cisplatin), containing therapy (intravenous or intraperitoneal) prior to randomisation: - Patients must have, in the opinion of the investigator, clinical complete response or partial response and have no clinical ...
Michael Scott, Undergraduate Medical Student. Referral of Women with Serous Ovarian Cancer, Fallopian Tube Cancer and Primary Peritoneal Cancer for BRCA 1/2 Genetic Testing ...
Question - How to determine whether the cyst in fallopian tube is beign or malignant?. Ask a Doctor about diagnosis, treatment and medication for Fallopian tube cancer, Ask an OBGYN, Gynecologic Oncology
An abnormal growth of malignant cells in one or both of a womans fallopian tubes. This is a rare type of tumor. There are several different types of fallopian tube cancer, including papillary serous adenocarcinomas, and occasionally leiomysosarcoma or transitional cell carcinomas.
Renavych - Patient: Ovarian and Fallopian Tube Cancer Patient Info: Living with cancer as a chronic illness (undergoing adjuvant therapy), Diagnosed: over 11 years ago, Female, Age: 72
pamholtzman - Patient: Ovarian and Fallopian Tube Cancer Patient Info: Newly diagnosed (has not begun treatment), Diagnosed: almost 6 years ago, Female, Age: 68
Dr. Shahabi is principal investigator for the following clinical protocols currently open at Northwestern:. NU 15G03 Partial wave spectroscopy (PWS) for ovarian cancer risk stratification and early detection among patients with high-risk heritable predisposition: developing standard operating procedures for automated PWS and a prediction rule for ovarian cancer screening. GOG 0225 Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube, and Primary Peritoneal Cancer Progression-Free Survival?. GOG 0238 A randomized trial of pelvic irradiation with or without concurrent weekly cisplatin in patients with pelvic-only recurrence of carcinoma of the uterine corpus. NRG-GY004 A Phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in women with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer. NRG-GY005 A Randomized Phase II/III study of the combination of Cediranib and Olaparib ...
The addition of bevacizumab (Avastin) to gemcitabine and carboplatin, followed by bevacizumab until disease progression, resulted in significantly improved progression-free survival compared to gemcitabine and carboplatin plus placebo among women with platinum-sensitive recurrent ovarian, primary periotoneal, or fallopian tube cancer. Results from the phase III OCEANS (Ovarian Cancer Study Comparing the Efficacy and Safety of Chemotherapy and Anti-Angiogenic Therapy in Platinum-Sensitive Recurrent Disease) trial were published in the Journal of Clinical Oncology.1 The study was sponsored by Genentech, which manufactures bevacizumab.. Analysis of Progression-free Survival. Both treatment groups consisted of 242 patients with histologically confirmed disease progression and ≥ 6 months after completion of front-line platinum-based chemotherapy. "At the time of the final [progression-free survival] analysis (338 events), the median follow-up was 24 months," the authors reported. The median ...
PRIMARY OBJECTIVES:I. To determine if women who are disease-free after successfully completing primary and potential consolidation/maintenance, therapy for
Cancer prevention is action taken to lower the chance of getting cancer. By preventing cancer, the number of new cases of cancer in a group or population is lowered. Hopefully, this will lower the number of deaths caused by cancer. To prevent new cancers from starting, scientists look at risk factors and protective...
Cancer prevention is action taken to lower the chance of getting cancer. By preventing cancer, the number of new cases of cancer in a group or population is lowered. Hopefully, this will lower the number of deaths caused by cancer. To prevent new cancers from starting, scientists look at risk factors and protective...
RATIONALE: Drugs used in chemotherapy, such as topotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by st
Patients with a histologic diagnosis of epithelial ovarian cancer, peritoneal primary carcinoma or fallopian tube cancer; International Federation of Gynecology and Obstetrics (FIGO) stage III with any gross (macroscopic or palpable) residual disease or FIGO stage IV, defined surgically at the completion of initial abdominal surgery and with appropriate tissue available for histologic evaluation; the minimum surgery required was an abdominal surgery providing tissue for histologic evaluation and establishing and documenting the primary site and stage, as well as a maximal effort at tumor debulking; if additional surgery was performed, it should have been in accordance with appropriate surgery for ovarian or peritoneal carcinoma described in the Gynecologic Oncology Group (GOG) Surgical Procedures Manual; however, the surgeon is not required to have performed all of the items contained in this section of the GOG Surgical Procedures Manual; those patients with stage III cancer in which the largest ...
The Food and Drug Administration (FDA) has approved Zejula (niraparib capsules; Tesaro) for the maintenance treatment of adults with recurrent epithelial o
Inclusion Criteria: - Patients must have platinum-sensitive, recurrent high-grade serous or high-grade endometrioid ovarian, primary peritoneal, or fallopian tube cancer. Submission of BRCA testing results is required for all patients. Patients with other (clear cell, mixed epithelial, undifferentiated carcinoma, or transitional cell carcinoma) high-grade histologies are also eligible, provided that the patient has a known deleterious germline BRCA1 or BRCA2 mutation identified through testing at a clinical laboratory. Due to the long acceptance of germline BRCA testing through Myriad, Myriad testing reports will be accepted without additional documentation. If testing for germline BRCA is done by other organizations, in addition to the testing report, documentation from a qualified medical professional (e.g., ovarian cancer specialty physician involved in the field, high risk genetics physician, genetics counselor) detailing the laboratory results is required. Please retain a copy of all ...
Oncolytics Biotech Inc. (Oncolytics) announced today that patient enrolment has started in a Phase 1/2 clinical trial for patients with metastatic ovarian, peritoneal and fallopian tube cancers using concurrent intravenous (IV) and intraperitoneal (IP)REOLYSIN®, Oncolytics proprietary formulation of the human reovirus. ... A cell with an activated Ras Pathway, which has lost its ability to…
Women with a grandmother, mother, daughter or sister with ovarian cancer but no known genetic mutation still have an increased risk of developing ovarian cancer. The lifetime risk of a woman who has a first degree relative with ovarian cancer is five percent (the average womans lifetime risk is 1.4 percent).. While it accounts for only a limited number of cases, heredity is a strong risk factor for ovarian cancer. Family history should be considered; however, many women without a family history may still have a gene mutation associated with risk for ovarian cancer. All women diagnosed with ovarian cancer, primary peritoneal or fallopian tube cancer should be referred for genetic counseling and consideration of genetic testing.. Family history of any of the following cancers may indicate an increased risk: Breast cancer, Ovarian cancer, Colon cancer, Uterine cancer, Rectal cancer.. ...
Making a film like this really helped me with not feeling ashamed, not feeling tainted, not feeling like there was something wrong with me," Rudnick said. "I inherited some bad DNA … but I think its given me a real desire to live and to enjoy life, and a blessing in knowing that I am healthy." For Rudnick, the odds arent good. One great-grandmother died of ovarian cancer, another of breast cancer; her grandmother developed breast cancer at age 56; and her mother was diagnosed with fallopian tube cancer at 44. It wasnt until the mid-1990s that scientists discovered that most inherited cases of breast cancer were associated with two genes: BRCA1 (Breast Cancer gene one) and BRCA2 (Breast Cancer gene two). Generally, the function of these genes is to keep breast cells growing normally and to prevent cancer cell growth. Mutated BRCA1 and BRCA2 genes, however, are associated with increased breast cancer risk and may account for up to 10 percent of all breast cancers. Women with mutated BRCA1 or ...
In a prior study, a group of women with advanced ovarian cancer were treated with 5 or 6 cycles of chemotherapy until there was no sign of active cancer. The women were then divided into two groups. One group had no further treatment, while the second group continued to receive additional chemotherapy. Cancer came back more quickly in the untreated group than in the group that continued to receive treatment. Unfortunately, in this trial it was not possible to determine if the delay in the return of their cancer was associated with an improvement in how long they lived. A second question that was not answered by this completed study was whether the benefit of the delay in the return of their cancer was outweighed by the side effects of continuing the chemotherapy. In the current trial the investigators wish to examine whether women with advanced ovarian, primary peritoneal or fallopian tube cancer who have no evidence of disease after the completion of initial chemotherapy live longer if a ...
Gregory Pawelski September 6, 2012 I first came across in 2003, the disparities in cancer care between the US and the UK in a clinical trial by Dr. Ian Cree, studying how well chemosensitivity assays predict response to chemotherapy in patients with persistent, refractory, or recurrent ovarian epithelial, peritoneal, or fallopian tube cancer. The results were highly suggestive of an effect due to the assay, and the most successful drug regimens used were nearly all developed using the assay. However, UK results in cancer are always lower than in the US for a variety of reasons. Part of this is probably lead time bias, but data on surgical debulking may be part of the explanation. Patients in the US get a whole lot more surgery along the way than in Europe. Even in the underpowered Cree, et al study, the use of his ATP assay changed treatment decisions in something like 90% of the cases, but the study was too small to show that the changed treatment decisions were to the benefit of the patient, ...
Hello Ladies,. I do not post on here very often now but try to read posts as often as I can. I am from the 2015 groups of womb/fallopian tube cancer.. Recently I feared there was a recurrence as I have had bowel problem and a lot of pain across my stomach which felt as if food that was being digested had to pass through shards of glass. So i did go to my GP who instigated an ultrasound scan,which basically showed there were no problems,but fortunately my GP sent me to a Consultant for the bowel. He then organised a CT scan, & suggested a Colonoscopy.. I had the colonoscopy procedure yesterday,& the Dr found 4 polyps one of which was 2cm in size. He removed all these & clamped them so that they would not bleed. This procedure took over an hour as it was quite tricky as there was scar tissue in the way from the hysterectomy & also a hernia from the hysterectomy. This procedure was very painful even though they put a canula in with appropriate medication. I asked if i could see everything on the ...
The other diagnostic test may include:. Ultrasound - Using high-frequency sound waves to produce a clear image of the peritoneum and other surrounding organs.. Blood Test - A CA-125 blood test will help to measure the level of certain chemicals in the blood stream of the patient.. Computerized Tomography (CT) scan - A high-definition image of the affected area us produced using this advanced imaging diagnostic technique.. Biopsy - This requires removing a portion of the tumor to send for detailed analysis in a pathological lab to determine the nature as well as the characteristics of the cancer cells. How is Peritoneal Cancer treated?. There are several different methods for treatment of peritoneal cancers. The exact type of treatment depends on various factors such as the stage of the cancer, its size and location as well as the patients overall health and age.. These are the various peritoneal cancer treatment methods:. Surgery. Surgical treatment is not only helpful in diagnosis of the ...
The ovaries are a pair of organs in the female reproductive system. They are in the pelvis, one on each side of the uterus (the hollow, pear-shaped organ where a fetus grows). Each ovary is about the size and shape of an almond. The ovaries make eggs and female hormones (chemicals that control the way certain cells or organs work). The fallopian tubes are a pair of long, slender tubes, one on each side of the uterus. Eggs pass from the ovaries, through the fallopian tubes, to the uterus. Cancer sometimes begins at the end of the fallopian tube near the ovary and spreads to the ovary.. The peritoneum is the tissue that lines the abdominal wall and covers organs in the abdomen. Primary peritoneal cancer is cancer that forms in the peritoneum and has not spread there from another part of the body. Cancer sometimes begins in the peritoneum and spreads to the ovary ...
Since the screening studies that investigated the utility of serum CA-125 and ultrasound did not improve survival rate, other screening modalities are aggressively pursued for ovarian HGSC.[13141518] Based on our current understanding of serous ovarian carcinogenesis, evidence pinpoints the etiologic significance of distal fallopian tubes.[111820] In keeping with this model, tubal lesions can potentially become a focal screening point for early detection of HGSC. Therefore, accurately detecting ovarian HGSC in its earlier stages is a promising concept which could provide earlier staging, adequate classification, and better prognostic outcomes. It has been shown that cytological diagnoses from fallopian fimbrial samples were correlative to histological diagnoses of HGSC.[18] However, due to the limited sample size that came from patients who already had clinical symptoms, the external validity is limited. Particularly given that the patients enrolled in those studies already had obvious clinical ...
Maintenance therapy is an important part of a cancer treatment regimen for patients who have responded positively to a primary treatment," said Richard Pazdur, MD, Acting Director of the Office of Hematology and Oncology Products in the FDAs Center for Drug Evaluation and Research, and Director of the FDAs Oncology Center of Excellence. "[Niraparib] offers patients a new treatment option that may help delay the future growth of these cancers, regardless of whether they have a specific genetic mutation.". Niraparib is a PARP inhibitor that blocks an enzyme involved in repairing damaged DNA. By blocking this enzyme, DNA inside the cancerous cells may be less likely to be repaired, leading to cell death and possibly a slow-down or stoppage of tumor growth.. The safety and efficacy of niraparib were studied in a randomized trial of 553 patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who had received at least two prior treatments of platinum-based ...
Patients must have with high-grade serous or endometroid ovarian, fallopian tube, or primary peritoneal cancer. Patients must have experienced a response lasting at least 6 months to first-line platinum-based therapy but currently considered to have platinum-resistant disease per investigators assessment (e.g, patient is not eligible for further platinum containing treatment). Patients may have had up to 4 lines of cytotoxic therapy for advanced or metastatic cancer. Neoadjuvant, adjuvant, and the combination of both will be considered as one line of therapy ...
Ovarian cancer is the leading cause of death among gynecologic diseases in Western countries. We have previously identified a miR-200-E-cadherin axis that plays an important role in ovarian inclusion cyst formation and tumor invasion. The purpose of this study was to determine if the miR-200 pathway is involved in the early stages of ovarian cancer pathogenesis by studying the expression levels of the pathway components in a panel of clinical ovarian tissues, and fallopian tube tissues harboring serous tubal intraepithelial carcinomas (STICs), a suggested precursor lesion for high-grade serous tumors. RNA prepared from ovarian and fallopian tube epithelial and stromal fibroblasts was subjected to quantitative real-time reverse-transcription polymerase chain reaction (qRT-PCR) to determine the expression of miR-200 families, target and effector genes and analyzed for clinical association. The effects of exogenous miR-200 on marker expression in normal cells were determined by qRT-PCR and fluorescence